Johnson & Johnson (JNJ) Provides Investors Positive Q3 Surprise
Tweet Send to a Friend
Get Alerts JNJ Hot Sheet
Price: $88.46 -0.15%
EPS Growth %: +5.1%
Financial Fact:
Interest income: -21M
Today's EPS Names:
NED, OESX, WSTL, More
EPS Growth %: +5.1%
Financial Fact:
Interest income: -21M
Today's EPS Names:
NED, OESX, WSTL, More
Trade JNJ Now!
Today blue chip medical company Johnson & Johnson (NYSE: JNJ) reported third quarter results that were, on the whole, better than expected.
For the third quarter of 2012, J&J reported EPS of $1.25, four cents better than analyst estimates, and 1 cent better than last year. Sales of $17.1 billion were slightly higher than estimates of $16.95 billion, and 6.5 percent higher than last year’s revenue of $16 billion.
The positive results were powered by a 13.4 percent increase in domestic sales and included the acquisition of Synthes, which contributed 5.8 percent to worldwide sales growth.
"We advanced our pipelines with regulatory approvals for a number of new products, the submission of several new drug applications, and the completion of several strategic collaborations," said Alex Gorsky, Chief Executive Officer, adding, "I have great confidence in our ability to deliver sustainable growth and bring meaningful innovations to patients and customers around the world."
Johnson & Johnson sees full-year 2012 EPS of $5.05-5.10, higher than prior guidance of $5.00-5.07. The consensus was for $5.06.
Shares of Johnson & Johnson last traded at $69.67, up 1.6 percent.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
For the third quarter of 2012, J&J reported EPS of $1.25, four cents better than analyst estimates, and 1 cent better than last year. Sales of $17.1 billion were slightly higher than estimates of $16.95 billion, and 6.5 percent higher than last year’s revenue of $16 billion.
The positive results were powered by a 13.4 percent increase in domestic sales and included the acquisition of Synthes, which contributed 5.8 percent to worldwide sales growth.
"We advanced our pipelines with regulatory approvals for a number of new products, the submission of several new drug applications, and the completion of several strategic collaborations," said Alex Gorsky, Chief Executive Officer, adding, "I have great confidence in our ability to deliver sustainable growth and bring meaningful innovations to patients and customers around the world."
Johnson & Johnson sees full-year 2012 EPS of $5.05-5.10, higher than prior guidance of $5.00-5.07. The consensus was for $5.06.
Shares of Johnson & Johnson last traded at $69.67, up 1.6 percent.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Hewlett-Packard Company (HPQ) Tops Q2 EPS by 6c as Sales Slide 10%
- Seaworld Ent. (SEAS) Narrows Q1 Loss to 49c/Share; Guides FY13 Revs
- Lowes Cos. (LOW) Misses Q1 EPS by 2c; Reaffirms FY13 Outlook
Create E-mail Alert Related Categories
Earnings, Hot Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
